Evidence map›Paper›PMID 27113370›Full record

ReviewCurrent oncology reports2016

Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas.

Philip Blumenfeld, Neilayan Sen, Ross Abrams, Dian Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Soft-tissue Sarcomas.Indian journal of orthopaedics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Philip BlumenfeldDepartment of Radiation Oncology, Rush University Medical Center, 500 S. Paulina, Suite 013, Chicago, IL, 60612, USA.
Neilayan SenDepartment of Radiation Oncology, Rush University Medical Center, 500 S. Paulina, Suite 013, Chicago, IL, 60612, USA.
Ross AbramsDepartment of Radiation Oncology, Rush University Medical Center, 500 S. Paulina, Suite 013, Chicago, IL, 60612, USA.
Dian WangDepartment of Radiation Oncology, Rush University Medical Center, 500 S. Paulina, Suite 013, Chicago, IL, 60612, USA. dian_wang@rush.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft tissue sarcomas (STS) consist of a heterogeneous group of rare malignancies arising from mesenchymal origin. While surgical resection is the primary treatment for STS, the use of radiotherapy (RT) as an adjunctive modality has been shown to improve oncologic outcomes. Technologic improvements, such as image guidance and intensity-modulated radiotherapy that significantly improve both the precision and delivery of RT, have led to the reduction of long-term RT toxicities without compromising outcomes. This review addresses these technologic advancements as well as discussing the most current updates regarding the use of brachytherapy, charged particles, and novel agents with RT.

Indexed as

BrachytherapyAdultHumansSarcomaIGRTIMRTNeoadjuvant radiotherapyRadiation therapySarcomaSBRTTargeted therapy

Identifiers

PMID27113370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.